Key Takeaway:
- PCOS renamed PMOS (Polyendocrine Metabolic Ovarian Syndrome) to better reflect its hormonal and metabolic nature.
- The change follows a 14-year global collaboration involving 50+ medical and patient organizations and input from over 22,000 participants.
- Experts say the new name will improve diagnosis, reduce stigma, and guide better long-term treatment worldwide.
A global coalition of medical experts and patient groups has renamed Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome to better reflect the complex hormonal disorder affecting more than 170 million women worldwide and improve diagnosis and care.
Experts Replace Misleading Name After Years of Research
Health organizations worldwide announce the condition formerly known as Polycystic Ovary Syndrome, or PCOS, will now be called Polyendocrine Metabolic Ovarian Syndrome, or PMOS, following a 14-year international collaboration, marking a major shift as PCOS Renamed PMOS.
More than 50 professional and patient organizations, including the Endocrine Society, participate in the effort, which researchers describe as the largest coordinated renaming of a medical condition. The findings and rationale for the change are published on Wednesday in The Lancet.
The condition affects about one in eight women globally and involves hormonal fluctuations influencing metabolism, weight, mental health, skin conditions, and reproductive health.
Professor Helena Teede of Monash University and Monash Health leads the initiative after decades of studying the disorder and its clinical impacts.
“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,” Teede says. She adds that the earlier name contributed to delayed diagnosis and inadequate treatment because it centered incorrectly on ovarian cysts.
Patient Input Drives Global Consultation and Cultural Shift
Researchers say the renaming process prioritizes patient experience alongside scientific accuracy. As PCOS Renamed PMOS reflects, more than 22,000 survey responses and multiple international workshops involving patients, clinicians, and researchers shape the final decision.
Professor Terhi Piltonen of Oulu University in Finland, an international co-lead of the project, says cultural sensitivity plays a major role in the change.
“It was essential that the new name was scientifically correct but also considered across diverse cultural contexts to avoid reproductive terms that could heighten stigma,” Piltonen says.
Rachel Morman, chair of Verity, a United Kingdom-based patient organization, says the previous name misrepresented the condition’s broader health risks.
“It is fantastic that the new name now leads with hormones and recognizes the metabolic dimension of the condition,” Morman says. “This shift will reframe the conversation and demand that it is taken as seriously as the long-term, complex health condition it is.”
A related research paper from the same experts finds no evidence of increased abnormal ovarian cysts, reinforcing the need for updated terminology.
Transition Period Begins Ahead of 2028 Global Guidelines
Health leaders say a three-year global transition period begins immediately, supported by an international education and awareness campaign targeting clinicians, governments, and researchers, following the announcement that PCOS Renamed PMOS.
The new terminology is expected to be fully adopted in the 2028 International Guideline update.
Teede says the renaming aims to reduce stigma, improve communication, and encourage earlier recognition of the disorder’s metabolic and endocrine aspects.
“The agreed principles of the new name included patient benefit, scientific accuracy, ease of communication, and avoidance of stigma,” she says, calling the decision a “landmark moment” for women’s health research and clinical practice.
Patient advocate Lorna Berry, who lives with the condition and participates in the consultation process, says the change represents long-awaited progress.
“This is about accountability and progress,” Berry says. “We deserve clarity, understanding, and equitable healthcare from the very beginning.”
Researchers hope the updated name will lead to improved screening, better long-term management, and expanded research investment for a condition historically misunderstood despite its widespread impact.
